Gynoflor (Estriol, Lactobacillus Acidophilus, Lyophilized)

Gynoflor is indicated for the local treatment of estrogen‑deficient conditions of the lower genital tract.

• Relief of vulvovaginal atrophy symptoms such as dryness, itching, and burning.
• Restoration of normal vaginal epithelium thickness.
• Re‑establishment of a healthy Lactobacillus‑dominant vaginal microbiota.
• Management of genitourinary syndrome of menopause (GSM) including dyspareunia.
• Adjunct therapy after systemic estrogen withdrawal or in women who cannot use systemic hormone therapy.

The safety profile of Gynoflor reflects the local estrogen exposure and the probiotic component.

Common

• Vaginal discharge or spotting.
• Mild irritation or burning sensation.
• Headache.
• Nausea.
• Increased vaginal secretions.

Serious

• Vaginal bleeding not related to menstrual cycle.
• Signs of estrogen‑dependent tumor growth (e.g., breast mass).
• Severe allergic reaction such as angioedema or anaphylaxis.
• Thromboembolic events (rare).
• Persistent pelvic pain.

Before prescribing Gynoflor, clinicians should consider several precautionary factors to ensure safe use.

• Not recommended for women with known estrogen‑dependent malignancies (e.g., breast, endometrial, ovarian cancer).
• Use with caution in patients with a history of thromboembolic disease.
• Avoid in active or untreated vaginal infections until resolved.
• Contraindicated during pregnancy and lactation unless benefits outweigh risks.
• Monitor for signs of abnormal uterine bleeding.
• Assess liver function in patients with severe hepatic impairment.

Gynoflor may interact with other medications or substances that influence estrogen activity or vaginal environment.

Avoid

• Systemic estrogen therapy (e.g., oral contraceptives, hormone replacement) due to additive estrogen effect.
• Antifungal or antibacterial vaginal agents taken concurrently, which may disrupt probiotic viability.

Use with caution

• Anticoagulants (e.g., warfarin) because estrogen can affect clotting factors.
• Selective estrogen receptor modulators (SERMs) as they may counteract estrogenic action.
• Hormonal chemotherapy agents.